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Abstract Tetrabromobisphenol A (2,2-bis(4-hydroxy-
3,5-dibromophenyl)propane; TBBPA) is a widely used
brominated flame retardant. TBBPA induces neuronal
damage, but the mechanism by which this occurs is largely
unknown. We studied the possible involvement of peroxi-
some proliferator-activated receptor gamma (PPAR-c) in
TBBPA-induced apoptosis and toxicity in mouse primary
neuronal cell cultures. TBBPA enhanced both, caspase-3
activity and lactate dehydrogenase (LDH) release in neo-
cortical cells after 6 and 24 h of exposition. These data were
supported at the cellular level with Hoechst 33342 staining.
Immunoblot analyses showed that, compared with control
cells, 10 lM TBBPA decreased the expression of PPAR-c
protein in neocortical neurons after 1–24 h of exposure. Co-
treatment with TBBPA and GW1929 inhibited the TBBPA-
induced caspase-3 activity, apoptotic body formation, and
LDH release as well as TBBPA-induced decrease in PPAR-c
protein expression. Thus, our data support neuroprotective
potential of PPAR-c agonists. The PPAR-c antagonist
GW9662 prevented the TBBPA-induced decrease in PPAR-
c protein level, but it potentiated TBBPA-induced apoptotic
and neurotoxic effects, which suggest that the mecha-
nism of TBBPA action in neuronal cells is not only
PPAR-c-dependent. Therefore, further studies of the
mechanism of TBBPA action in the nervous system are
needed.
Keywords TBBPA  PPAR-c  Neurotoxicity 
Apoptosis  Neocortex  GW1929
Introduction
Tetrabromobisphenol A (2,2-bis(4-hydroxy-3,5-dibrom-
ophenyl)propane; TBBPA) is a widely used brominated
flame retardant (BFR). TBBPA is used as a replacement for
the polybrominated diphenylethers (PBDEs), which are
persistent environmental BFRs that have documented
negative effects on human health (Talsness et al. 2009;
Kicin´ski et al. 2012). TBBPA can be utilized both as a
reactive flame retardant in epoxy resin-printed circuit
boards and as an additive flame retardant in a wide variety
of commercial and household products, such as plastics,
textiles and electronic appliances, including computers and
televisions (Alaee et al. 2003; Covaci et al. 2009; de Wit
et al. 2010). This versatility has resulted in a dramatic
increase in TBBPA production. Several studies have shown
that when this component is used as an additive in poly-
mers, it can be easily released from the treated products
(Sellstrom and Jansson 1995; Birnbaum and Staskal 2004).
Despite its short half-life, TBBPA may accumulate in tis-
sues following repeated exposure (Sjo¨din et al. 2003).
Although many studies indicate that rats and humans
quickly metabolize TBBPA due to its rapid conjugation
with glucuronic acid and elimination in the bile, TBBPA
has been detected in cow and human milk, serum, adipose
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tissue and umbilical cord serum (Thomsen et al. 2002;
Johnson-Restrepo et al. 2008). In human serum samples
0.24–0.71 ng of TBBPA/g lipid were reported which is
equal to 1.8–5.3 pM, using a conversion factor of 400 mg
lipid/100 ml serum (Thomsen et al. 2002). Although the
half-life of TBBPA is about 2 days in humans, continuous
uptake of this compound may increase its concentrations
and potentiate toxicological effects of TBBPA (Sjo¨din et al.
2003). According to toxicokinetic study of Schauer et al.
(2006), a single oral dose of 300 mg/kg TBBPA to adult
humans resulted in a plasma concentration of over 100 lM
within 3 h of exposure, and this level was maintained for
approximately 6 h (elimination half-life of 13 h). There-
fore, living organisms may be temporally exposed to even
higher concentrations of TBBPA than they have been
reported in plasma or urine samples. As numerous studies
have demonstrated, TBBPA causes pathological changes in
many organs, particularly the thyroid and liver, and it
negatively affects the immune and reproductive systems
(Van der Ven et al. 2008; Kibakaya et al. 2009). TBBPA
also has carcinogenic properties, which means that expo-
sure to this compound may lead to the development of
numerous types of cancers (Shi et al. 2010). In addition,
TBBPA accumulates in different brain regions and induces
behavioral alterations (Nakajima et al. 2009; Viberg and
Eriksson 2011). However, only a few studies have investi-
gated the mechanism through which TBBPA acts. TBBPA
was recently shown act as a peroxisome proliferator-acti-
vated receptor gamma (PPAR-c) ligand in NIH3T3-L1 cells
(Riu et al. 2011a).
PPAR-c is a ligand-activated transcription factor that
belongs to the nuclear receptor superfamily. It regulates the
expression of genes that are related to metabolic processes
and reducing inflammation. Importantly, PPAR-c is widely
expressed in the brain, where it has a crucial role in the
regulation of nervous cell proliferation, differentiation, and
apoptosis. PPAR-c has a protective function in neurons. Yi
et al. (2009) showed that PPAR-c activation confers neu-
roprotection through anti-inflammatory, anti-apoptotic, and
anti-oxidative mechanisms. In addition, the activation of
PPAR-c receptor ameliorates neurodegenerative diseases
(Kitamura et al. 1999; Heneka et al. 2000; Garrido-Gil
et al. 2012). Although PPAR-c activation reduces brain
tissue damage in experimental models of brain diseases
(Pereira et al. 2006; Tureyen et al. 2007; Zhao et al. 2011;
Ridder and Schwaninger 2012), how PPAR-c activity is
regulated in neurons is unclear.
The aim of this study was to investigate the effect of
TBBPA on the viability and apoptosis of mouse neocortical
neurons at 7 days in vitro (DIV) after 6 and 24 h of
exposure. To explore the mechanism of TBBPA action on




Neurobasal medium without phenol red and B27 supple-
ment were purchased from Life Technologies. Trypsin,
charcoal/dextran-treated fetal bovine serum, penicillin,
streptomycin, TRIS, HEPES, CHAPS, DTT, EDTA,
Tween 20, bromophenol blue, staurosporine, TBBPA, and
DMSO were purchased from Sigma-Aldrich (St. Louis,
MO, USA). The PPAR-c agonist GW1929 and the PPAR-c
antagonist GW9662 were purchased from Sigma-Aldrich.
Stock solutions of these test compounds were prepared in
DMSO and were added to Neurobasal medium. The final
concentration of DMSO in the culture medium was always
0.1 %. The cytotoxicity lactate dehydrogenase (LDH)
detection kit was purchased from Roche Applied Science
(Germany).
Primary Neocortical Cell Cultures
The experiments were performed on primary cultures of
mouse cortical neurons. The primary cultures of neocorti-
cal neurons were prepared from the fetuses of pregnant
female Swiss mice as previously described in detail
(Brewer 1995; Kajta et al. 2005). Brain tissues were col-
lected from mouse embryos on days 15 or 16 of gestation.
Pregnant females were anesthetized with CO2 vapor and
killed by cervical dislocation. Animal care followed offi-
cial governmental guidelines, and all efforts were made to
minimize the number of animals used and their suffering.
All procedures were performed in accordance with the
National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals and were approved by the
Bioethics Commission, as compliant with Polish law.
Brains were removed from fetuses and the cortical tis-
sues were dissected. The dissected tissue was minced into
small pieces and then gently digested with trypsin and
DNAse I. Then, the cells were centrifuged, and the pellet
was resuspended in phenol red-free Neurobasal medium
(Life Technologies) supplemented with 5 % fetal calf
serum. Cells were plated onto poly-L-ornithine (0.01 mg
per ml)-coated multi-well plates. After 2 days, the culture
medium was exchanged to Neurobasal medium supple-
mented with B27 (2 lL/mL), glutamine (2 mM), 50 U/mL
penicillin, and 0.05 mg/mL streptomycin, which is rec-
ommended for primary neuronal cultures (Brewer 1995;
Kajta et al. 2005). This procedure typically yields cultures
that contain about 90 % neurons and 10 % astrocytes
(Kajta et al., 2004). The cultures were maintained at 37 C
in a humidified atmosphere containing 5 % CO2 and were
cultivated for 7 days in vitro prior to the experiment. The
culture medium was changed prior to treating cultures with
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all compounds selected for this study. Then, primary neo-
cortical cell cultures were exposed to experimental doses of
TBBPA for 6 h or 24 h.
Treatment
For the experiments, the cells were plated in 96-well plates
at a density 2 9 105 cells per cm2 and cultured in the pre-
sence of TBBPA, in a concentrations range from 1 nM to
100 lM TBBPA. TBBPA was dissolved in DMSO, result-
ing in a final vehicle concentration of 0.1 % (v/v). Control
(no vehicle) and DMSO-treated wells were included in the
experimental design to determine the effect of DMSO
(result not shown). To study whether PPAR-c is involved in
the neurotoxic effect of TBBPA, cells were co-treated with
10 lM TBBPA and 10 lM GW1929 or GW9662. After 6
or 24 h of culture, 100 ll medium was collected for the
LDH analysis, and the cells were collected and frozen at
-70 C for the caspase-3 activity measurements.
LDH Cytotoxicity Assay
The cytotoxicity detection kit (Roche Applied Science,
Germany) is a colorimetric assay for the quantification of
cell death and cell lysis based on the LDH activity released
from the cytosol of damaged cells into the supernatant. An
increase in the amount of dead or plasma membrane-
damaged cells results in an increase in the LDH activity in
the culture supernatant. After 6 or 24 h of treatment with
the rising concentrations of TBBPA, 100 ll of the culture
supernatants was collected and incubated with the reaction
mixture from the kits. After 30 min, the reaction was
stopped by adding 1 N HCl, and the absorbance was
measured at a wavelength of 490 nm with a reference
wavelength of 600 nm in the microELISA plate reader
Bio-Tek Instruments (Biokom).
Caspase-3 Activity
Caspase-3 activity was used as a marker for cell apoptosis
and was assessed according to Nicholson et al. (1995).
Cultured neurons were lysed with a lysis buffer (50 mM
HEPES, pH 7.4, 100 mM NaCl, 0.1 % CHAPS, 1 mM
EDTA, 10 % glycerol, 10 mM DTT). Lysates were incu-
bated with the caspase-3 substrate Ac-DEVD-pNA (N-
acetyl-Asp-Glu-Val-Asp-p-nitroanilide; Sigma-Aldrich) at
37 C. Cells treated with 1 lM staurosporine were used as a
positive control. After 30 min, the absorbance of the lysates
was measured at 405 nm in a microplate reader (Bio-Tek
ELx800). The amount of colorimetric product was moni-
tored continuously for 120 min. Data were analyzed with
KCJunior (Bio-Tek Instruments) and normalized to the
absorbance in vehicle-treated cells. The results are
expressed as the mean % of control from eight separate
samples ±SEM, and samples were run in quadruplicate.
Western Blot Analysis
For immunoblotting, the cells were lysed in ice-cold lysis
buffer containing 50 mM HEPES, 100 mM NaCl, 0.1 %
CHAPS, 1 mM EDTA, 10 % glycerol, and 10 mM DTT.
Then, the lysates were sonicated and clarified by centri-
fugation at 15.0009g at 4 C for 30 min. The protein
concentrations in the supernatants were determinate with
the Bradford reagent (BioRad Protein Assay; BioRad
Laboratories, Munchen, Germany) using bovine serum
albumin (BSA) as the standard. From the whole explant
lysate, 100 lg of total protein was reconstituted in the
appropriate amount of sample buffer, consisting of
125 mM Tris, pH 6.8, 4 % SDS, 25 % glycerol, 4 mM
EDTA, 20 mM DTT, and 0.01 % bromophenol blue.
Samples were separated by 7.5 % SDS–polyacrylamide gel
electrophoresis in a Bio-Rad Mini-Protean II Electropho-
resis Cell, and the proteins were then transferred to nitro-
cellulose membranes using a Bio-Rad Mini Trans-Blot
apparatus. Following the transfer, the membranes were
washed, and nonspecific binding sites were blocked with
5 % dried milk and 0.2 % Tween 20 in 0.02 M TBS for
2 h. Then, the membranes were incubated overnight with
the PPAR-c receptor antibody (goat anti-human polyclonal
antibody, Santa Cruz Biotechnology, Inc.) diluted at 1:100
in TBS/Tween at 4 C. After incubation with the primary
antibody, the membranes were washed with TBS and
0.02 % Tween 20 and incubated for 2 h with horseradish
peroxidase-conjugated secondary antibody (donkey anti-
goat IgG, Santa Cruz Biotechnology, Inc.) diluted at 1:500
in TBS/Tween. To control for the amount of protein that
was loaded onto the gel, the membranes were stripped and
reprobed with an anti-b-actin antibody (Sigma-Aldrich).
Signals were detected by chemiluminescence (ECL) using
a Western Blotting Luminol Reagent (Santa Cruz Bio-
technology, Inc.) and visualized with the use of a Syngene
GBOX and GeneSnap software.
Identification of Apoptotic Cells with Hoechst 33342
Staining
Apoptotic cells exhibit nuclear condensation and DNA
fragmentation, which can be detected by vital staining with
Hoechst 33342 (Sigma-Aldrich). For this purpose, neurons
were seeded on polyornithine-coated coverslips placed in
24-well plates at a density of 2.5 9 105/well and were ini-
tially cultured for 7 days to allow for differentiation. Then,
the medium was changed to Neurobasal supplemented with
B27 in the presence of 10 lM of TBBPA, and the cells were
cultured for an additional 24 h. After this period, the cells
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were washed with PBS and exposed to Hoechst 33342.
Hoechst 33342 was diluted with PBS and added to the
medium at a final concentration of 10 lM. Cells were
incubated for 15 min in an atmosphere of 5 %CO2/95 % air
at 37 C and then visualized with a fluorescent microscope
(Nikon, Japan).
Statistical Analysis
Data are presented as the mean ± SEM of four indepen-
dent experiments. Each treatment was repeated eight times
(n = 8) and run in quadruplicate; thus, the total number of
replicates was 32. The average of the quadruplicate sam-
ples was used for the statistical calculations. Data were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s multiple comparison procedure.
Results
Effects of TBBPA on Caspase-3 Activity in Neocortical
Primary Cell Cultures (7 DIV)
Caspase-3 activity significantly increased following
TBBPA exposition for 6 h at doses of 1, 10, 50, and
100 lM of TBBPA compared with the vehicle control
(Fig. 1a). These concentrations of TBBPA increased cas-
pase-3 activity compared with the vehicle control (33.6,
49.8, 84.4, and 165.8 %, respectively). After 24 h of
exposure, the increase in caspase-3 activity was dose-
dependent, starting from the 100 nM concentration. The
caspase-3 activity induced by the exposure to 100 nM and
1, 10, 50 and 100 lM TBBPA increased compared with the
vehicle control (94.4, 177.7, 240.7, 319.4, and 416.7 %,
respectively) (Fig. 1b).
Effects of TBBPA on LDH Release in Neocortical
Primary Cell Cultures (7 DIV)
In neocortical cell cultures, after 6 and 24 h of exposure to
10, 50, or 100 lM TBBPA, LDH activity was increased
compared with the vehicle control (71.4, 244.9, and
468.6 %, respectively, after 6 h; 169.4, 326.2, and
636.9 %, respectively, after 24 h) (Fig. 2a, b).
Effect of TBBPA on the Expression of PPAR-c
in Neocortical Cell Cultures
Immunoblot analyses showed that, compared with control
cells, 10 lM of TBBPA decreased the level of PPAR-c
protein in neocortical neurons after 1–24 h of exposure




























































Fig. 1 The effect of increasing
concentrations of TBBPA (1,
10, 50, and 100 nM and 1, 10,
50, and 100 lM) on caspase-3
activity in cultured neocortical
neurons cells after 6 a and 24
b h of exposure. Cell treated
with 1 lM of staurosporine
were used as a positive control.
Each point represents the
mean ± SEM of four
independent experiments, each
of which consists of eight
replicates per treatment group.
***p \ 0.001, **p \ 0.01, and
*p \ 0.05 versus the control
cultures
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as in the presence of TBBPA did not affect the PPAR-c
protein level (Fig. 4a, b). All samples had equal protein
concentrations, as verified based on the expression of b-
actin (loading control).
Effects of the PPAR-c Agonist on TBBPA-Stimulated
Caspase-3 Activity and TBBPA LDH Release
in Neocortical Cell Cultures
In the presence of PPAR-c agonist GW1929, the TBBPA-
induced caspase-3 increase was diminished. Pre-treating
neuron cultures with GW1929 inhibited caspase-3 activity,
compared with TBBPA treatment, by 57.7 and 94.5 % after 6
and 24 h of exposure, respectively (Fig. 5a). The cytotoxic
effect of 10 lM TBBPA, measured based on LDH release, in
the presence of GW1929 was also inhibited after 6 and 24 h
of exposure to 51.3 and 90.8 %, respectively, compared with
the TBBPA-stimulated LDH release (Fig. 5b).
Effects of the PPAR-c Antagonist on TBBPA-
Stimulated Caspase-3 Activity and TBBPA LDH
Release in Neocortical Cell Cultures
The opposite effect was observed when cells were
co-treated with PPAR-c antagonist GW9662 and 10 lM
TBBPA. After 6 and 24 h of treatment, caspase-3 activity
was 38.7 and 22.8 %, respectively (Fig. 6a). Pretreating
cells with GW9662 enhanced the cytotoxic effect of
TBBPA, and LDH release was increased by 114.2 and
81.2 % after 6 and 24 h of exposition, respectively,
compared with the TBBPA-stimulated LDH release
(Fig. 6b).
Effect of TBBPA on Hoechst 33342 Staining
in Neocortical Cell Cultures
To confirm that apoptosis was induced, the neurocortical
neurons were stained with Hoechst 33342 to show DNA
fragmentation. Apoptotic bodies appeared as bright blue
fragmented nuclei that showed condensed chromatin,
which is typical of apoptotic cells. In the control culture,
healthy cells with intact nuclei and diffuse fluorescence
were mostly observed (Fig. 7a). The apoptotic bodies were
observed in cells after 24 h of exposure to 10 lM TBBPA
(Fig. 7b) or to co-treatment with GW9662 and 10 lM of
TBBPA (Fig. 7f). In cells cultured in the presence of the
PPAR-c agonist GW1929 and 10 lM TBBPA (Fig. 7d),
























































Fig. 2 The effect of increasing
concentrations of TBBPA (1,
10, 50, and 100 nM and 1, 10,
50, and 100 lM) on LDH
activity in cultured neocortical
neurons cells after 6 a and 24
b h of exposure. Data are the
mean ± SEM of four
independent experiments, each
of which consists of eight
replicates per treatment group.
***p \ 0.001 versus the control
cultures
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Discussion
This study demonstrated that micromolar concentrations of
TBBPA treatment has a cytotoxic effect, indicated by LDH
release in mouse neocortical cell cultures, after as little as
6 h of incubation. Our data also showed that TBBPA could
induce caspase-3 activity and apoptotic body formation in
these cells. Furthermore, the apoptotic effects were induced
by lower concentrations of TBBPA than were required to
induce LDH release. These results suggest that in primary
Time after 10µM TBBPA 































Fig. 3 Representative Western
blot of PPAR-c protein levels in
neocortical neurons treated with
10 lM of TBBPA for 0, 1, 3, 6,
and 24 h (a). PPAR-c bands
were quantified by
densitometry. The results are
shown as the percentage of
PPAR-c protein relative to the
control. Each column represents
the mean ± SEM of three
independent experiments (b).
The blots were stripped and
reprobed with anti-b-actin
antibody to control for the
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GW1929 GW9662      
b
a
Fig. 4 Representative Western
blot of PPAR-c protein levels in
neocortical neurons treated with
TBBPA (10 lM); GW1929
(10 lM); cells co-treated with
GW1929 (10 lM) and TBBPA
(10 lM); GW9662 (10 lM);
cells co-treated with GW9662
(10 lM) and TBBPA (10 lM)
(a). PPAR-c bands were
quantified by densitometry. The
results are shown as the
percentage of PPAR-c protein
relative to the control. Each
column represents the
mean ± SEM of three
independent experiments (b).
The blots were stripped and
reprobed with anti-b-actin
antibody to control for the
amounts of protein loaded onto
the gel
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neocortical cell cultures, TBBPA induces cell death by
caspase-3-dependent apoptosis, and then the cells undergo
secondary necrosis. Similar results were previously obtained
by Reistad et al. (2007), who showed that micromolar con-
centrations of TBBPA-induced apoptotic body formation
and DNA fragmentation followed by the cerebellar granule
cell death. In contrast to our study, these authors did not
detect activation of caspase-3, and suggested a caspase-
independent mechanism of TBBBA-induced apoptotic cell
death. Interestingly, TBBPA-induced caspase-3-dependent
apoptosis was observed in rat pheochromocytoma PC-12 and
SH-SY5Y human neuroblastoma cells (Al-Mousa and Mi-
chelangeli 2012; Hendriks et al. 2012). In addition to above
mentioned apoptotic effects, TBBPA may increase intra-
cellular calcium level, induce reactive oxygen species for-
mation, as well as to activate microglia and cytokine
synthesis.
Recent studies on TBBPA affinity to nuclear receptors
showed that intracellular actions of TBBPA are mediated by
PPAR-c (Riu et al. 2011a, b). The ability of TBBPA to
activate PPAR-c receptors were demonstrated in reported
cell lines (HeLa cells), zebrafish, and Xenopus. These
authors, however, studied only TBBPA-binding affinity to
PPAR-c, but not TBBPA-induced apoptosis and toxicity.
Therefore, we hypothesize that in our study, PPAR-c is
involved in apoptotic effects of TBBPA in neuronal cells.
We demonstrated that PPAR-c protein is expressed in mouse
neocortical cell cultures. The presence of PPAR-c has pre-
viously been documented in various areas of the adult brain
and spinal cord and the highest level of PPAR-c expression
was observed in human and mouse neural stem cells (Cris-
tiano et al. 2001; Moreno et al. 2004; Cimini et al. 2005;
Wada et al. 2006; Chiang et al. 2013). It has been postulated
that in the nervous system PPAR-c regulates the apoptosis
and neurotoxicity (Kim et al. 2003; Akasaki et al. 2006; Gray
et al. 2012; Zeng et al. 2012). The recent study showed that
activation of PPAR-c down-regulated caspase-3 activity and
viability of human neuronal stem cells, and protected murine
cortical neurons against ischemia (Kaundal and Sharma
2011; Zeng et al. 2012; Chiang et al. 2013). However, the
mechanism underlying the cytotoxic and pro-apoptotic



















































Fig. 5 The effect of 10 lM of
TBBPA on the caspase-3 a and
LDH b activity in the presence
of PPAR-c agonist GW1929 in
neocortical neuron cultures after
6 and 24 h of exposure. Cell
treated with 1 lM of
staurosporine were used as a
positive control. Data are the
mean ± SEM of four
independent experiments, each
of which consists of eight
replicates per treatment group.
***p \ 0.001 and **p \ 0.01
versus the control group;
###p \ 0.001 and ##p \ 0.01
versus the TBBPA-stimulated
group
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Our study demonstrated that TBBPA-induced apoptosis
in neuronal cells which was accompanied by reduction of
PPAR-c protein expression, much below the control level.
Treatment with PPAR-c agonist GW1929 did not change
control levels of any measured parameter. Co-treatment
with TBBPA and GW1929 inhibited the TBBPA-induced
caspase-3 activity, apoptotic body formation, and LDH
release as well as TBBPA-induced decrease in PPAR-c
protein expression. Our data support neuroprotective
potential of PPAR-c agonists. The protective effects of
PPAR-c agonists have been shown in many experimental
models of brain injury, including cerebral ischemia
(Shimazu et al. 2005; Chu et al. 2006; Pereira et al. 2006;
Tureyen et al. 2007; Zhao et al. 2009; Kim et al. 2011),
NMDA-induced cytotoxicity (Zhao et al. 2006, 2007), and
Parkinson’s disease (Schintu et al. 2009; Ridder and Sch-
waninger 2012).
In our study, by the use of PPAR-c antagonist GW9662,
we demonstrated that co-treatment with GW9662 potenti-
ated the neurotoxic effects of TBBPA and only partially
restored the TBBPA-mediated decrease in the PPAR-c
protein expression. Treatment with PPAR-c antagonist
GW9662 did not influence control levels of any studied
parameter. These data point to specific antagonistic action
of GW9662 on PPAR-c protein level, but suggest non-
specific action of GW9662 on TBBPA-induced neurotox-
icity. Cytotoxic effects of PPAR-c antagonist were also
observed by Bishop-Bailey et al. (2000) in ECV403 cells
treated with bisphenol A derivative, BADGE. Interestingly,
the authors demonstrated increased transcriptional activity
of PPAR-c in BADGE-treated cells. This result might be
related to the partial restoration of PPAR-c protein level in
TBBPA and GW9662-treated neocortical cells, as observed
in our study. There are controversies about antagonistic/
agonistic potency of PPAR-c antagonists. Most of avail-
able data showed that PPAR-c antagonists (BADGE,
GW9662) reversed the neuroprotective effects of PPAR-c
agonists, e.g., in SK-N-SH neuronal cells exposed to
ischemia, in animal model of Parkinson’s disease (Kim
et al. 2011; Garrido-Gil et al. 2012; Zeng et al. 2012). In
contrast, BADGE exhibited agonistic properties when it


























































Fig. 6 Effect of 10 lM of
TBBPA on caspase-3 a and
LDH b activity in the presence
of PPAR-c antagonist GW 9662
in neocortical neuron cultures
after 6 and 24 h of exposure.
Cell treated with 1 lM of
staurosporine were used as a
positive control. Data are the
mean ± SEM of four
independent experiments, each
of which consists of eight
replicates per treatment group.
***p \ 0.001 and **p \ 0.01
versus the control group;
##p \ 0.01 versus the TBBPA-
stimulated group
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(Bishop-Bailey et al. 2000). In our study, we used GW9662
which is known to act as irreversible PPAR-c antagonist.
We demonstrated that GW9662 did not antagonize, but
potentiated toxic effects of TBBPA in neocortical cells.
This effect point to non-PPAR-c-specific effects of
GW9662. Accordingly, non-PPAR-c-specific effects of
GW9662 were also reported in breast cancer and colorectal
carcinoma cells (Seargent et al. 2004; Schaefer et al. 2007).
We hypothesize, that in our study paradigm, TBBPA
exhibited properties of PPAR-c inverse agonist, i.e., it
inhibited constitutive activity of the receptor. Our study
demonstrated that TBBPA caused substantial decrease in
PPAR-c protein expression, much below the control level,
which supports our hypothesis. Co-treatment of TBBPA
with PPAR-c agonist GW1929 inhibited the TBBPA-
induced effect and normalized PPAR-c protein level, but
Fig. 7 The effect of TBBPA on Hoechst 33342 staining in neocor-
tical neuron cell cultures, examined 24 h post treatment, a control
cells; b TBBPA-treated cells (10 lM); c GW1929-treated cells;
d cells co-treated with GW1929 (10 lM) and TBBPA (10 lM);
e GW9662-treated cells; f cells co-treated with GW9662 (10 lM) and
TBBPA (10 lM). Cells with light-colored cytoplasm were identified
as living cells. Cells with bright fragmented nuclei showing
condensed chromatin were identified as undergoing apoptosis.
Photomicrographs are shown in 9200 magnification
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not above the control level. It is possible that both TBBPA
and GW1929 competed for the same binding site on the
receptor, thus the effect of PPAR-c agonist GW1929 was
compromised by PPAR-c inverse agonist TPPBA. Fur-
thermore, co-treatment of TBBPA with PPAR-c agonist
GW1929 inhibited the TBBPA-induced apoptosis and
toxicity. Less conclusive were data on the effects of co-
treatment of TBBPA with PPAR-c antagonist GW9662.
We demonstrated that GW9662 antagonized the TBBPA-
induced decrease in PPAR-c protein level, but it did not
antagonized the TBBPA-induced apoptosis and cytotoxic-
ity. These effects suggest that GW9662 may not be specific
PPAR-c antagonist in neuronal cells. Moreover, one may
assume that TBBPA action on neuronal cells is only par-
tially mediated by PPAR-c, thus its actions may only be
partially affected by PPAR-c antagonist.
Conclusion
In conclusion, our results provide a line of evidence indi-
cating that PPAR-c is involved in the mechanism of TBBPA
action in neuronal cells. TBBPA-induced caspase-3 activity,
apoptotic body formation and LDH release in neuronal cells
and reduced the PPAR-c protein expression below the con-
trol level. TBBPA-induced effects were inhibited by the
PPAR-c agonist GW1929. The PPAR-c antagonist GW9662
prevented the TBBPA-induced decrease in the PPAR-c
protein expression. However, it potentiated TBBPA-induced
apoptotic and neurotoxic effects, which suggest that the
mechanism of TBBPA action in neuronal cells is not only
PPAR-c-dependent. Therefore, further studies of the mech-
anism of TBBPA action in the nervous system are needed.
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